Classement en actions
#29600
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Prix de l'action
$0.93739396
Dernière synchronisation: 2026-01-08
Capitalisation boursière
$20.44M
Changement (1 jour)
0.60%
Échange Ulisse Biomed S.p.A. (UBM)
Le prix UBM avec la capitalisation boursière de B
Capitalisation boursière de Ulisse Biomed S.p.A.(UBM)
Capitalisation boursière: $20.44M
En August 2026, Ulisse Biomed S.p.A. a une capitalisation boursière de $20.44M. Cela fait de Ulisse Biomed S.p.A. la 29600th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Ulisse Biomed S.p.A. du 2021 au 2026
UBM par rapport au top 5 des plus populaires stocks
| Prix pour UBM |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.307T
|
+25,962,013.18%
|
|
|
|
|
$4.551T
|
+22,264,070.89%
|
|
|
|
|
$4.154T
|
+20,324,863.37%
|
|
|
|
|
$3.589T
|
+17,556,640.26%
|
|
|
|
|
$2.797T
|
+13,683,298.50%
|
